Gain Therapeutics, Inc
A clinical-stage biotechnology company working on diseases caused by misfolded proteins, including Parkinson's disease, where its lead drug candidate GT-02287 aims to help restore a key enzyme. Founded in 2017 in Lugano, Switzerland, it uses its AI-driven Magellan platform to spot hard-to-reach spots on disease-related proteins. The name reflects the goal of "gaining" control over protein function—and access to pockets long considered undruggable.
Bought 50.0K
Granted 54.9K · Bought 17.0K
Bought 30.0K
Granted 24.2K · Sold 2.0K
Bought 14.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Islam KhalidExecutive Chairman, Director · 1 transaction | — | 930.8Kas of Aug 2024 | — | 50.0K | — |
| Richman Eric IDirector · 3 transactions | +30.9% | 304.5Kas of Jul 2024 | 54.9K | 17.0K | — |
| Riley Jeffrey ScottDirector · 1 transaction | — | 30.0Kas of Mar 2024 | — | 30.0K | — |
| Alder MatthiasChief Executive Officer, Director · 9 transactions | +725% | 27.2Kas of Mar 2024 | 24.2K | — | 2.0K |
| Mack GeneCFO and Interim CEO · 1 transaction | — | 14.4Kas of Aug 2024 | — | 14.4K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +109.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.